These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 10828870)

  • 1. Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide.
    Afify Z; Shaw PJ; Clavano-Harding A; Cowell CT
    Bone Marrow Transplant; 2000 May; 25(10):1087-92. PubMed ID: 10828870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth and endocrine function following bone marrow transplantation for thalassemia major.
    Li CK; Chik KW; Wong GW; Cheng PS; Lee V; Shing MM
    Pediatr Hematol Oncol; 2004; 21(5):411-9. PubMed ID: 15205084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
    Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases.
    Tauchmanovà L; Selleri C; Rosa GD; Pagano L; Orio F; Lombardi G; Rotoli B; Colao A
    Cancer; 2002 Sep; 95(5):1076-84. PubMed ID: 12209694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Endocrinal sequela in bone marrow transplantations during childhood and adolescence].
    Le Heup B; von Bueltzingloewen A; Bordigoni P; Sommelet D; Pierson M
    Ann Pediatr (Paris); 1993 Sep; 40(7):463-8. PubMed ID: 8239398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg).
    Grigg AP; McLachlan R; Zaja J; Szer J
    Bone Marrow Transplant; 2000 Nov; 26(10):1089-95. PubMed ID: 11108308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pubertal development and final height after autologous bone marrow transplantation for acute lymphoblastic leukemia.
    Frisk P; Arvidson J; Gustafsson J; Lönnerholm G
    Bone Marrow Transplant; 2004 Jan; 33(2):205-10. PubMed ID: 14628079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
    Michel G; Socié G; Gebhard F; Bernaudin F; Thuret I; Vannier JP; Demeocq F; Leverger G; Pico JL; Rubie H; Mechinaud F; Reiffers J; Gratecos N; Troussard X; Jouet JP; Simonin G; Gluckman E; Maraninchi D
    J Clin Oncol; 1997 Jun; 15(6):2238-46. PubMed ID: 9196136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation.
    Shaw PJ; Bergin ME; Burgess MA; Dalla Pozza L; Kellie SJ; Rowell G; Stevens MM; Webster BH; Bradstock KF
    J Clin Oncol; 1994 Oct; 12(10):2138-45. PubMed ID: 7931485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term side-effects in children receiving allogeneic bone marrow transplantation in first complete remission of acute leukaemia.
    Thuret I; Michel G; Carla H; Chambost H; Blaise D; Demeocq F; Maraninchi D
    Bone Marrow Transplant; 1995 Mar; 15(3):337-41. PubMed ID: 7599556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth in children undergoing bone marrow transplantation after busulfan and cyclophosphamide conditioning.
    Shankar SM; Bunin NJ; Moshang T
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):362-6. PubMed ID: 8888742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
    Gaziev D; Galimberti M; Polchi P; Angelucci E; Giardini C; Baronciani D; Andreani M; Persini B; Erer B; Sodani P; Manna M; Nicolini G; Visani G; Lucarelli G;
    Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late effects in children after bone marrow transplantation: a review.
    Locatelli F; Giorgiani G; Pession A; Bozzola M
    Haematologica; 1993; 78(5):319-28. PubMed ID: 8314162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth after bone marrow transplantation in young children conditioned with chemotherapy alone.
    Adan L; de Lanversin ML; Thalassinos C; Souberbielle JC; Fischer A; Brauner R
    Bone Marrow Transplant; 1997 Feb; 19(3):253-6. PubMed ID: 9028555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure.
    Teinturier C; Hartmann O; Valteau-Couanet D; Benhamou E; Bougneres PF
    Bone Marrow Transplant; 1998 Nov; 22(10):989-94. PubMed ID: 9849696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-dose busulfan with subsequent bone marrow transplantation in poor-risk forms of leukemia].
    Urban C; Slavc I; Kaulfersch W; Teubl I
    Wien Klin Wochenschr; 1987 Mar; 99(5):144-9. PubMed ID: 3554777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Busulphan/cyclophosphamide conditioning for bone marrow transplantation may lead to failure of hair regrowth.
    Baker BW; Wilson CL; Davis AL; Spearing RL; Hart DN; Heaton DC; Beard ME
    Bone Marrow Transplant; 1991 Jan; 7(1):43-7. PubMed ID: 2043877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants.
    Al-Fiar FZ; Colwill R; Lipton JH; Fyles G; Spaner D; Messner H
    Bone Marrow Transplant; 1997 May; 19(10):1019-22. PubMed ID: 9169646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.